Eli Lilly (LLY) is trading at $1,457.43, just under its immediate resistance band, while Jefferies raised its price target to $1,700 and kept a Buy rating on November 9, 2026. The stock’s trend str...
Eli Lilly (LLY) is still pressing higher in a firmly bullish structure, with the current price at $1,457.43, above the 7-day, 20-day, 50-day, 12-day EMA and 26-day EMA. That matters because the moving-average stack remains constructive: MA7 sits above MA20, which sits above MA50, a classic trend-confirmation pattern rather than a reflex bounce.
The problem is that the stock is also running close to resistance. The 24-hour range reached $1,461.78 on the high side, while immediate resistance is marked at $1,470.21 and strong resistance at $1,483.00. With RSI at 70.02 and price sitting near the upper Bollinger Band at $1,482.34, the setup is extended even if the broader trend remains intact.
Lilly’s own third-quarter 2026 update, released October 29, is the fundamental anchor here. Revenue rose 39% to $24.4 billion, driven mainly by Mounjaro and Zepbound, and the company raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 billion to $92.0 billion. It also increased underlying non-GAAP EPS guidance at the midpoint by $4.07, according to Lilly’s release.
That is the kind of earnings reset that can support a higher stock price, but the market has already responded aggressively. The current technical posture suggests the easy part of the move may have happened first, while the next leg depends on whether buyers can prove they still have sponsorship above the $1,470 area.
Source link







